<DOC>
	<DOCNO>NCT00002817</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill melanoma cell . PURPOSE : Phase I/II trial study effectiveness vaccine therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity intralesional immunotherapy recombinant vaccinia virus encode gene sargramostim ( GM-CSF ) patient metastatic melanoma . II . Determine efficiency viral infection GM-CSF gene insertion function patient . III . Determine capacity regimen generate antiviral antitumor immunity patient . IV . Determine frequency regression inject uninjected lesion patient . OUTLINE : This dose-escalation study intralesional recombinant vaccinia virus encode gene sargramostim ( GM-CSF ) ( rV-GM-CSF ) . Patients stratify center . Patients receive small pox ( vaccinia ) vaccine via multipuncture technique day 0 . On day 4 , patient progressive major reaction initial vaccination receive rV-GM-CSF intralesionally twice weekly 5 week . Only 1 lesion treat least 1 measurable lesion leave untreated patient . Patients respond disease week 5 retreat clinically appropriate dose schedule . Cohorts 5 patient receive escalate dos intralesional rV-GM-CSF maximum tolerate dose ( MTD ) determine . Additional patient receive rV-GM-CSF MTD . PROJECTED ACCRUAL : Approximately 30 patient ( 15 phase ) accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven melanoma consider surgically incurable Dermal , subcutaneous , lymph node metastasis require At least 3 lesion evaluable accessible injection biopsy One lesion least 10 mm diameter No leukemia lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 6 month Hematopoietic : Not specify Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) SGOT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 3 time ULN Immunologic : Clinical evidence immune response require within 4 day smallpox vaccination At least 1 positive cutaneous delayedtype hypersensitivity response 1 following : Microbial recall antigens Dinitrofluorobenzene sensitization Purified protein derivative tuberculin follow BCG vaccination No alter immunocompetence ( e.g. , immune deficiency disease immunosuppressive therapy ) patient household contact No allergy follow : Polymyxin B sulfate Streptomycin sulfate Chlortetracycline hydrochloride Neomycin sulfate No history eczema exfoliative skin condition patient household contact HIV negative Other : No malignancy within past 3 year except superficial squamous cell basal cell skin cancer carcinoma situ cervix prostate Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 8 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent imminent steroid therapy Radiotherapy : At least 8 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>